Skip to main content
TipRanks
Go Ultimate75% OFF

Sandoz Group Ltd Sponsored ADR (SDZNY) AI Stock Analysis

94 Followers
SDZNY

Sandoz Group Ltd Sponsored ADR

(Other OTC:SDZNY)

Select Model
Rating:71Outperform
Price Target:$113.00â–²(16.89% Upside)
Action:upgraded
Date:11/06/26

Improving financial performance and strong earnings-call momentum support the score, reinforced by favorable technical trends. The main constraint is expensive valuation, while overbought technical readings and pricing, legal, and CapEx pressures add risk.

Positive Factors
Biosimilar Growth and PipelineStrong biosimilar growth and a broad 36-asset pipeline increase Sandoz’s exposure to higher-growth products and future launches. This expanding platform can support sustained revenue development, diversify the portfolio, and reinforce the company’s position in biologic medicines over multiple years.
Negative Factors
Pricing ErosionThe higher expected pricing decline directly threatens revenue quality and can offset volume gains, particularly in competitive generics and biosimilars. Persistent erosion would pressure gross margins and require continued launches, productivity gains, or mix improvement to protect profitability.

Sandoz Group Ltd Sponsored ADR (SDZNY) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%60%SDZNY+43.87%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$41.80B
Dividend Yield
1.06%
Average Volume (3M)
20.55K
Price to Earnings (P/E)
64.9
Beta (1Y)
0.71
Revenue Growth
9.56%
EPS Growth
180.05%
Country
US
Employees
23,000
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Sandoz Group Ltd Sponsored ADR Business Overview & Revenue Model

Company Description

Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharma...

Sandoz Group Ltd Sponsored ADR Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:21.68%|Next Earnings Date:Mar 13, 2024
Earnings Call SentimentPositive

The call presented a broadly positive performance story: strong biosimilar-led top-line growth, margin expansion, resilient cash generation despite a significant CapEx cycle, an enlarged 36-asset biosimilar pipeline, major product launches with leading market shares, and strategic investments (Ljubljana center) that support medium-term growth. Near-term challenges include increased pricing erosion (now expected mid-single-digit), temporary generics headwinds (notably in Q1 and in some international markets), short-term tender/pricing disruption in Germany, elevated one-off and settlement-related cash outflows, and a heavier CapEx profile in 2026. Management reaffirmed 2026 guidance and emphasized confidence in 2027–2028 growth driven by upcoming launches and the multisource GLP-1 strategy. On balance, the positives around revenue momentum, profitability improvement, pipeline breadth, and strong commercial execution outweigh the near-term operational and pricing headwinds.

Positive Updates

Top-line Growth
Net sales increased 5% in H1 (10% in USD) to USD 5.8bn with accelerating momentum into Q2 (+7% overall; North America +15% H1, +18% Q2).

Negative Updates

Generics Headwinds
Generics experienced a modest decline in H1 due to temporary headwinds (notably adverse anti-infectives B2B dynamics in Q1); generics only returned to low single-digit growth in Q2.

Company Guidance

Management confirmed 2026 guidance: net sales are expected to increase mid‑ to high‑single‑digit at constant currencies (H1 sales were USD 5.8bn, +5% cc), core EBITDA margin is targeted to expand by around 100 basis points (H1 margin 20.9%, +90bps Y/Y), and overall pricing is now expected to decline by a mid‑single‑digit percentage in 2026 (revised from a prior low‑to‑mid‑single‑digit view). They now assume a ~2 percentage‑point FX tailwind to net sales for the year (previously ~4pp) and still do not expect material FX impact on the core EBITDA margin; CapEx is expected to peak this cycle at ~USD 1.1bn (H1 CapEx ≈ USD 500m) while management free cash flow remained around USD 500m in H1, one‑off costs are expected at ~USD 0.3bn for the year, and the balance sheet targets include net debt/EBITDA below 2x (net debt ≈ USD 3.5bn, net‑debt-to-core‑EBITDA 1.4x, gross debt USD 5.9bn, liquidity USD 2.3bn, average borrowing cost <4%).

Sandoz Group Ltd Sponsored ADR Financial Statement Overview

Summary

Stable gross margins, improving 2025 profitability, stronger cash flow, and manageable leverage support the score. Revenue softness, historical cash-flow volatility, and ROE below 10% remain limitations.

Income Statement

72Positive

Balance Sheet

68Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue11.62B11.15B10.38B11.66B9.30B9.62B
Gross Profit5.52B5.24B4.93B5.33B4.38B4.54B
EBITDA2.48B2.26B742.00M1.00B1.73B1.87B
Net Income645.84M919.12M1.00M89.99M847.75M907.82M
Balance Sheet
Total Assets22.79B22.03B19.91B22.71B17.55B17.48B
Cash, Cash Equivalents and Short-Term Investments1.25B1.74B1.19B1.30B80.01M39.86M
Total Debt6.20B5.68B4.85B5.32B4.18B4.93B
Total Liabilities13.79B12.65B11.74B12.59B8.80B9.35B
Stockholders Equity9.00B9.38B8.16B10.10B83.41K8.12B
Cash Flow
Free Cash Flow1.22B810.00M60.00M-307.36M821.99M935.82M
Operating Cash Flow1.72B1.59B656.00M423.06M1.22B1.35B
Investing Cash Flow-2.06B-980.00M-740.00M-717.57M-464.93M-690.87M
Financing Cash Flow159.95M-197.00M242.00M1.45B-831.47M-656.87M

Sandoz Group Ltd Sponsored ADR Technical Analysis

Technical Analysis SentimentPositive
Last Price96.67

Price Trends

50DMA91.44Positive
100DMA88.38Positive
200DMA85.43Positive

Market Momentum

MACD2.29Positive
RSI47.87Neutral
STOCH2.77Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SDZNY, the sentiment is Positive. The current price of 96.67 is below the 20-day moving average (MA) of 100.21, above the 50-day MA of 91.44, and above the 200-day MA of 85.43, indicating a neutral trend. The MACD of 2.29 indicates Positive momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 2.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SDZNY.

Sandoz Group Ltd Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SDZNY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
KNSAKNSA80Outperform$7.47B66.4717.27%―58.19%192.34%
CORTCORT76Outperform$7.42B45.1922.94%―30.02%48.80%
SDZNYSDZNY71Outperform$43.31B64.907.04%1.06%9.56%180.05%
LQDALQDA60Neutral$5.08B-54.76-116.64%―798.44%27.88%
SCYXSCYX53Neutral$28.07M-2.41-18.65%―543.96%72.49%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BFRIBFRI38Underperform$10.65M-1.50-110.30%―29.85%78.56%

* Healthcare Sector Average

Performance Comparison

0%100%200%SDZNYCORTSCYXKNSALQDABFRIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SDZNY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SDZNYSandoz Group Ltd Sponsored ADR96.6731.0247.26%
CORTCorcept Therapeutics67.79-7.26-9.67%
SCYXSCYNEXIS Inc2.82-2.70-48.91%
KNSAKiniksa Pharmaceuticals Ltd. Class A95.0553.56129.09%
LQDALiquidia Technologies56.4027.8497.48%
BFRIBiofrontera, Inc.0.60-0.15-20.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026